Pasithea Therapeutics (KTTA) vs Marker Therapeutics (MRKR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Marker Therapeutics (MRKR) has outperformed Pasithea Therapeutics (KTTA) over the past year, losing 12.0% versus a loss of 40.8%. Over five years, MRKR leads with a -94.0% price change compared with -99.2% for KTTA. Marker Therapeutics is the larger company by market cap ($16.2 million vs $15.6 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | KTTA | MRKR |
|---|---|---|
| Share price | $0.4675 | $0.9716 |
| Market cap | $15.62M | $16.20M |
| 1-day change | +6.03% | +2.27% |
| YTD return | -63.76% | -36.24% |
| 1-year return | -40.82% | -12.04% |
| 5-year return | -99.22% | -94.03% |
| EPS (TTM) | $-1.59 | $-0.42 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.06 | $2.46 |
| 52-week low | $0.281 | $0.84 |
| Distance from 52-week high | -77.31% | -60.50% |
| Analyst consensus | none | none |
| Avg. price target upside | +541.71% | +710.00% |
| Average volume | 225.69K | 65.70K |
| Shares outstanding | 33.41M | 16.67M |
| Employees | 5 | 5 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- MRKR has outperformed KTTA by 28.8 percentage points over the past year.
About Pasithea Therapeutics
KTTA stock →Pasithea Therapeutics Corp., a clinical-stage biotechnology company, focuses on the discovery, research, and development of treatments for central nervous system (CNS) disorders, RASopathies, and cancers. Its lead product candidate is PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor to treat a range of RASopathies, including neurofibromatosis type 1 (NF1); MAPK pathway-driven tumors, such as BRAFv600 and BRAF fusion tumor; and ETS2 driven diseases, including inflammatory bowel disease (IBD), primary sclerosing cholangitis, and ankylosing spondylitis.
Health Care · Biotechnology: Pharmaceutical Preparations · 5 employees
About Marker Therapeutics
MRKR stock →Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, develops and commercializes T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications in the United States. The company's multi antigen recognizing (MAR)-T cell therapy technology is based on the selective expansion of non-engineered tumor-specific T cells that recognize tumor-associated antigens and kill tumor cells expressing those targets.
Health Care · Biotechnology: Pharmaceutical Preparations · 5 employees
KTTA vs MRKR FAQ
Which is bigger, Pasithea Therapeutics or Marker Therapeutics?
Marker Therapeutics (MRKR) is larger, with a market capitalization of $16.20M compared with $15.62M for Pasithea Therapeutics (KTTA).
Which stock has performed better over the past year, KTTA or MRKR?
MRKR returned -12.04% over the past 12 months, compared with -40.82% for KTTA (price return, excluding dividends). Past performance does not predict future results.
Are Pasithea Therapeutics and Marker Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.